Akcea licenses exclusive worldwide rights to amyloidosis compounds from Ionis in $1.9bn deal
Ionis Pharmaceuticals Inc. granted Akcea Therapeutics Inc. worldwide exclusive rights to inotersen (ISIS420915; TEGSEDI) and AKCEA-TTR-LRx in exchange for payments totaling up to $1.9bn plus royalties.
- Antisense, Oligonucleotides
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.